These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 24323838)

  • 1. Continuous drug delivery in Parkinson's disease.
    Senek M; Nyholm D
    CNS Drugs; 2014 Jan; 28(1):19-27. PubMed ID: 24323838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update.
    Nyholm D
    Clin Pharmacokinet; 2006; 45(2):109-36. PubMed ID: 16485914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged-release.
    Rascol O
    Eur J Neurol; 2011 Mar; 18 Suppl 1():3-10. PubMed ID: 21255197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Continuous dopaminergic stimulation - clinical experience].
    Bogucki A; Sławek J
    Neurol Neurochir Pol; 2010; 44(4):385-95. PubMed ID: 20827612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New dopaminergic therapies for PD motor complications.
    Larson D; Simuni T
    Neuropharmacology; 2022 Feb; 204():108869. PubMed ID: 34742740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New treatments for the motor symptoms of Parkinson's disease.
    Vijverman AC; Fox SH
    Expert Rev Clin Pharmacol; 2014 Nov; 7(6):761-77. PubMed ID: 25318835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Continuous dopaminergic delivery to minimize motor complications in Parkinson's disease.
    Wright BA; Waters CH
    Expert Rev Neurother; 2013 Jun; 13(6):719-29. PubMed ID: 23739008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic optimisation in the treatment of Parkinson's disease.
    Contin M; Riva R; Albani F; Baruzzi A
    Clin Pharmacokinet; 1996 Jun; 30(6):463-81. PubMed ID: 8792058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medical management of levodopa-associated motor complications in patients with Parkinson's disease.
    Jankovic J; Stacy M
    CNS Drugs; 2007; 21(8):677-92. PubMed ID: 17630819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and pharmacodynamics of levodopa/carbidopa cotherapies for Parkinson's disease.
    Müller T
    Expert Opin Drug Metab Toxicol; 2020 May; 16(5):403-414. PubMed ID: 32238065
    [No Abstract]   [Full Text] [Related]  

  • 11. Constant dopaminergic stimulation by transdermal delivery of dopaminergic drugs: a new treatment paradigm in Parkinson's disease.
    Steiger M
    Eur J Neurol; 2008 Jan; 15(1):6-15. PubMed ID: 18042245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in the delivery of treatments for Parkinson's disease.
    Johnston TH; Fox SH; Brotchie JM
    Expert Opin Drug Deliv; 2005 Nov; 2(6):1059-73. PubMed ID: 16296809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safinamide for the treatment of Parkinson's disease.
    Kandadai RM; Jabeen SA; Kanikannan MA; Borgohain R
    Expert Rev Clin Pharmacol; 2014 Nov; 7(6):747-59. PubMed ID: 25300164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
    Deleu D; Hanssens Y; Northway MG
    Drugs Aging; 2004; 21(11):687-709. PubMed ID: 15323576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current strategies in the drug treatment of advanced Parkinson's disease--new modes of dopamine substitution.
    Schelosky L; Poewe W
    Acta Neurol Scand Suppl; 1993; 146():46-9. PubMed ID: 8101415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving the Delivery of Levodopa in Parkinson's Disease: A Review of Approved and Emerging Therapies.
    Urso D; Chaudhuri KR; Qamar MA; Jenner P
    CNS Drugs; 2020 Nov; 34(11):1149-1163. PubMed ID: 33146817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Continuous Drug Delivery Aiming Continuous Dopaminergic Stimulation in Parkinson's Disease.
    van Wamelen DJ; Grigoriou S; Chaudhuri KR; Odin P
    J Parkinsons Dis; 2018; 8(s1):S65-S72. PubMed ID: 30584160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infusional Therapies, Continuous Dopaminergic Stimulation, and Nonmotor Symptoms.
    Mundt-Petersen U; Odin P
    Int Rev Neurobiol; 2017; 134():1019-1044. PubMed ID: 28805563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continuous dopaminergic delivery in Parkinson's disease.
    Antonini A; Ursino G; Calandrella D; Bernardi L; Plebani M
    J Neurol; 2010 Nov; 257(Suppl 2):S305-8. PubMed ID: 21080194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and efficacy of a novel formulation of carbidopa-levodopa (Accordion Pill
    LeWitt PA; Giladi N; Navon N
    Parkinsonism Relat Disord; 2019 Aug; 65():131-138. PubMed ID: 31176632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.